BUHLMANN News

BUHLMANN Quantum Blue® TDM Tutorial

View this demonstration of quantitative trough level measurement for TDM using the Quantum Blue^® TDM rapid test technology.

Quantum Blue^® Adalimumab:
Health Canada License: 101776

Quantum Blue^® Infliximab:
Health Canada License: 98838

US: (The Quantum Blue^® tests are for Research Use Only. Not for use in diagnostic procedures.)

Contact BUHLMANN Today!

Contact us & learn more about our Quantum Blue^® rapid tests & Quantum Blue^® Reader.

The Quantum Blue^® rapid test combines the ease and speed of lateral flow technology (using a highly specific monoclonal antibody), with full quantification by means of a small, telephone sized reading device. The Quantum Blue^® Reader analyzes the signal intensity from the test and control line to give a quantitative value.

Download Nulled WordPress Themes

Download WordPress Themes

Free Download WordPress Themes

Download Best WordPress Themes Free Download

ZG93bmxvYWQgbHluZGEgY291cnNlIGZyZWU=

download coolpad firmware

Download WordPress Themes

udemy free download

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.